Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients

Research output: Contribution to journalArticle

Abstract

N-Methyl d-aspartate (NMDA)-receptor hypofunction has been implicated in the pathophysiology of schizophrenia and d-serine and glycine add-on therapy to antipsychotics has shown beneficial effects in schizophrenic patients. Nevertheless, previous studies have not shown consistently altered d-serine concentrations in cerebrospinal fluid (CSF) of schizophrenic patients. To confirm and extend these results, CSF concentrations of both endogenous NMDA-receptor co-agonists d-serine and glycine and their common precursor l-serine were analyzed simultaneously in 17 healthy controls and 19 schizophrenic patients before and 6 weeks after daily olanzapine (10 mg) treatment. CSF d-serine, l-serine and glycine concentrations and their relative ratios were similar between schizophrenic patients and controls and no differences were observed before and after olanzapine therapy. Thus, the NMDA-receptor hypofunction hypothesis in schizophrenia is not explained by olanzapine therapy-dependent absolute or relative decreases in CSF d-serine and glycine concentrations in this series of male patients, thereby not providing convenient markers for the disorder.

Details

Authors
  • Sabine A. Fuchs
  • Martina M.J. De Barse
  • Floor E. Scheepers
  • Wiepke Cahn
  • Lambertus Dorland
  • Monique G. de Sain-van der Velden
  • Leo W.J. Klomp
  • Ruud Berger
  • René S. Kahn
  • Tom J. de Koning
External organisations
  • University Medical Center Utrecht
Research areas and keywords

Keywords

  • Cerebrospinal fluid, d-Serine;, Glycine;, NMDA-receptor;, Olanzapine;, Schizophrenia;
Original languageEnglish
Pages (from-to)333-338
JournalEuropean Neuropsychopharmacology
Volume18
Issue number5
Publication statusPublished - 2008 May 1
Publication categoryResearch
Peer-reviewedYes
Externally publishedYes